Russian pharmaceutical companies face new governance and liability obligations by structure. What in-house counsel must assess now. Make an enquiry.
Recent developments in Russian corporate and regulatory practice have sharpened the consequences of a decision that many foreign pharmaceutical groups have historically treated as administrative convenience: whether to operate in Russia through a registered branch or through a locally incorporated subsidiary. Under changes that took effect progressively through 2024 and 2025, the governance requirements, the liability exposure of senior managers, and the regulatory obligations owed to Roszdravnadzor now diverge more materially depending on structural form than at any point in the preceding decade. For in-house counsel managing a Russian pharmaceutical operation, the branch vs subsidiary question in Russia is no longer a matter of tax efficiency alone — it is a matter of who bears liability when things go wrong.
Before the changes that crystallised in 2024–2025, the practical distinction between a branch and a subsidiary in the Russian pharmaceutical context was real but manageable. A branch of a foreign legal entity operated without separate legal personality, binding the parent directly to Russian law obligations; a subsidiary, incorporated as a Russian legal entity, interposed a liability buffer and a separate governance layer. Both could hold pharmaceutical licences; both could interact with Roszdravnadzor, the federal regulator responsible for pharmaceutical oversight; both could conclude local employment contracts. The differences mattered, but they were differences of degree rather than kind.
Two developments have shifted that calculus. First, Russian corporate practice has seen a marked tightening of the accountability standards applied to the heads of branches — referred to in Russian law as branch representatives or authorised representatives. Under the prevailing interpretation applied by Russian courts since mid-2024, the head of a branch, acting under a general power of attorney from the foreign parent, can now be treated as falling within the category of individual debtors under Russian civil and insolvency legislation in circumstances where the branch's obligations to counterparties or regulators go unmet. This is not a statutory amendment in the traditional sense; it is a doctrinal consolidation that Russian courts have applied consistently, and which the Russian Supreme Court has declined to disturb. The practical consequence is that branch representatives face a materially higher risk of personal subsidiary liability than was previously understood to attach to this role.
Second, Roszdravnadzor has updated its inspection and enforcement guidance to distinguish more precisely between the compliance obligations of branches and those of locally incorporated entities. Subsidiaries are now expected to maintain a locally resident general director with full signatory authority and a local compliance officer accountable for Good Distribution Practice obligations. Branches, by contrast, operate under the compliance framework of the foreign parent — which means that when Roszdravnadzor issues a corrective order or initiates a suspension proceeding, the enforcement addressee is the parent entity directly, not a Russian intermediary that can be wound up or restructured in isolation.
For foreign pharmaceutical groups — particularly those with significant EAEU distribution operations — these two shifts interact. A branch structure that was chosen for its operational simplicity may now expose the parent to direct regulatory enforcement and its senior representative to individual liability. A subsidiary structure that was chosen for liability containment may now require a governance uplift that brings its own compliance burden.
"In the pharmaceutical sector, the branch vs subsidiary question is rarely just structural — it determines whether individual managers face direct liability and whether Roszdravnadzor can impose corrective measures on the parent." — Stanislav Lastovsky, Senior Lawyer, Practice Lead — Restructuring & Insolvency, Vetrov & Partners
The companies most directly affected are those operating a branch structure in Russia that predates the 2024 guidance consolidation — particularly where the branch head holds a broad general power of attorney and where the branch has accumulated material obligations to Russian counterparties, employees, or the state.
The risk profile is sharpest for three categories of foreign pharmaceutical operator. The first is the multinational with a legacy branch registration that was established before Russia's 2012–2015 wave of pharmaceutical localisation requirements, and which has not been reviewed structurally since. These branches often carry powers of attorney that were drafted for a different regulatory environment and which, under current court interpretation, create broader personal liability for the branch representative than the drafters intended.
The second category is the mid-sized European or EAEU-domiciled manufacturer distributing its own products through a Russian branch rather than through a local distributor or subsidiary. Where the branch is the direct licence holder for pharmaceutical import or distribution, and where that licence is tied to the personal accountability of the branch head under Roszdravnadzor's current enforcement posture, the individual liability risk is compounded by the regulatory enforcement risk.
The third category is the foreign parent that has restructured its Russian operations since 2022 — reducing headcount, shrinking the compliance function, or allowing the governance documentation of its Russian branch to fall out of date. Under the current framework, gaps in local governance documentation are not merely administrative untidiness. For a branch, they are potential grounds for Roszdravnadzor to treat the parent's Russian operations as non-compliant and to address enforcement action to the parent directly. For a subsidiary, the same gaps may trigger director liability proceedings against the general director under Russian corporate legislation.
Under Russian insolvency legislation, preferential liability claims may be brought against controlling persons — including branch representatives who have exercised control over the branch's financial obligations — in respect of transactions completed over a three-year look-back period. In-house counsel who have not recently reviewed whether their Russian branch head meets the definition of a controlling person under the current interpretation should treat this as a live governance priority.
For in-house counsel managing a Russian pharmaceutical operation with a branch structure, this is the moment to commission a structural review before Roszdravnadzor's inspection cycle reaches your entity.
If your Russian pharmaceutical operation runs through a branch structure that has not been reviewed since 2022 — make an enquiry: info@vetrovpartners.com |
The practical response to these developments follows a clear sequence, and timing matters. Roszdravnadzor's enforcement calendar for 2026 is expected to include increased scrutiny of foreign-linked pharmaceutical entities, in line with the regulator's published inspection priorities.
The first step is a structural audit of the Russian entity — branch or subsidiary — covering three specific points: the scope of any existing power of attorney held by the branch representative, the currency of the governance documents (including local compliance officer appointment and GDP compliance records), and whether the branch or subsidiary holds the pharmaceutical licence in its own name or through an arrangement with a third party.
The second step is a liability mapping exercise. This means identifying every category of obligation that the Russian entity has assumed — contractual, regulatory, tax, employment — and assessing whether those obligations, if unmet, would expose the branch representative personally, the foreign parent directly, or both. This exercise is not complex in itself, but it requires someone who understands both the Russian civil law treatment of individual debtors and the Roszdravnadzor enforcement framework simultaneously. The two analyses interact in ways that a purely corporate or purely regulatory review will miss.
The third step is a decision on structural form going forward. For some groups, the answer will be to convert the existing branch into a subsidiary — a process governed by Russian civil legislation and requiring re-registration of the pharmaceutical licence. For others, the answer will be to retain the branch but substantially upgrade its governance documentation and narrow the power of attorney held by the branch representative. For a smaller number, the commercially correct answer may be to close the branch entirely and operate through a third-party distributor, which removes the direct regulatory exposure but requires careful management of the distribution agreement to avoid creating the same exposure indirectly.
Each option carries its own procedural timeline. A branch-to-subsidiary conversion in the pharmaceutical sector typically involves regulatory interaction with both the Federal Tax Service and Roszdravnadzor, and should be budgeted at a minimum of six months from the decision to act. Governance upgrades to an existing branch, by contrast, can be completed in weeks — but they are only effective if the underlying power of attorney and liability-bearing arrangements are addressed at the same time, not merely the visible compliance documents.
The firm acted for a European pharmaceutical distributor in a structural review of its Russian branch arrangements, advising on governance uplift and the reallocation of personal liability risk from the branch representative to a properly constituted subsidiary, with concurrent Roszdravnadzor licensing coordination — completed within nine months of initial instructions.
For further context on the general branch vs subsidiary framework in Russia, see the firm's Branch vs Subsidiary Decision: Governance and Liability in Russia and the Comparative Analysis: Branch vs Subsidiary Decision.
The firm's Corporate Governance practice advises foreign pharmaceutical companies on Russian entity structuring, governance compliance, and Roszdravnadzor engagement. For cross-border restructuring matters touching Restructuring & Insolvency considerations — including individual liability for branch representatives — the firm's practices work in conjunction.
Two areas of interpretive uncertainty remain live as of January 2026 and are worth flagging for foreign pharmaceutical groups planning structural changes this year.
The first concerns the precise threshold at which a branch representative's conduct rises to the level of controlling person for insolvency liability purposes. Russian courts have applied this analysis inconsistently across circuits, and there is no Supreme Court ruling that cleanly resolves the question in the pharmaceutical context. Companies converting branches to subsidiaries should not assume that conversion alone removes historic liability exposure for the branch representative — the look-back analysis runs from the date of the relevant transaction, not from the date of conversion.
The second open question is how Roszdravnadzor will treat pharmaceutical licences that are held by a branch that subsequently converts to a subsidiary. The current regulatory guidance does not provide a safe harbour for licence continuity through a structural conversion, and the regulator retains discretion to treat the new subsidiary as a fresh applicant for the relevant licence categories. Groups planning conversions in 2026 should seek regulatory confirmation on this point before commencing the conversion process.
Q: What specifically changed in the Russian regulatory framework governing branch and subsidiary structures in the pharmaceutical sector?
A: The changes are doctrinal and regulatory rather than a single statutory amendment. From 2024, Russian courts have consolidated an interpretation under which branch representatives — acting under general powers of attorney from foreign parent companies — can be treated as individual debtors under Russian civil and insolvency legislation when branch obligations go unmet. Simultaneously, Roszdravnadzor updated its enforcement guidance to address compliance obligations differently depending on whether the Russian entity is a branch or a locally incorporated subsidiary. The combined effect is that the liability and regulatory exposure of the two structural forms have diverged materially from where they sat before 2024.
Q: Which foreign companies operating in Russia are most directly affected by these developments?
A: Three categories are most exposed. First, foreign pharmaceutical groups with legacy branch registrations that predate the 2015 pharmaceutical localisation wave and that have not been structurally reviewed since. Second, EAEU-domiciled or European manufacturers distributing through a Russian branch where the branch head is also the pharmaceutical licence holder. Third, foreign parents that have reduced their Russian compliance function since 2022 without updating the underlying power of attorney or governance documents. In each case, the exposure runs both to the branch representative personally and, in the Roszdravnadzor enforcement context, to the parent entity directly.
Q: What steps should in-house counsel take to assess their current structure?
A: The minimum assessment covers three points: the scope of the power of attorney held by the branch representative; the currency of governance and GDP compliance documentation; and the basis on which the pharmaceutical licence is held. From that baseline, a liability mapping exercise identifies where individual debtor exposure sits, and a structural decision — convert, upgrade governance, or close — follows. The timeline for a branch-to-subsidiary conversion in the pharmaceutical sector should be budgeted at a minimum of six months, given the interaction with Roszdravnadzor licensing. Governance upgrades to an existing branch can be completed more quickly, but only if the power of attorney is addressed concurrently.
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry